The anti-CCR4 monoclonal antibody mogamulizumab has cytotoxic effects on ATLL cells, although the response rate may be improved by combining mogamulizumab with chemotherapy during the acute stage .19 The gene discussed is CCR4; the disease is adult T-cell leukemia/lymphoma.